On June 12, GenScript Biotech rose 5.07% in regular trading, trading at HK$12.44/share, with turnover of HK$520 million. The rally coincides with the ongoing EHA (European Hematology Association) annual meeting where subsidiary Legend Biotech is presenting breakthrough clinical data.

Legend Biotech is delivering a Late-Breaking Oral Presentation at the EHA conference (June 11-14) showcasing preliminary Phase 1 clinical data for LB2501, a CD19/CD20 dual-target in-vivo CAR-T therapy for relapsed/refractory B-cell non-Hodgkin lymphoma. Previously disclosed data showed 100% overall response rate and 83.3% complete remission rate in the second dose-level cohort of 6 patients, with no dose-limiting toxicities or serious adverse events observed. Analysts have characterized LB2501 as a disruptive breakthrough in cell therapy with the potential to make CAR-T treatments broadly accessible by eliminating the need for lymphodepletion chemotherapy and supporting outpatient administration.

The broader Life Sciences Tools and Services sector also traded positively, with Wuxi XDC up 4.80%, Wuxi Biologics up 3.54%, and XtalPi up 2.78%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)